Idiopathic Pulmonary Fibrosis Market Growth Outlook: Trends, Market Size, and Opportunities Over the Next Decade
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the Idiopathic Pulmonary Fibrosis Market?
An increase in the occurrence of fibrotic diseases is projected to stimulate the expansion of the idiopathic pulmonary fibrosis market. Fibrotic diseases, commonly known as fibrosis, encompass a variety of health conditions marked by an overproduction and aggregation of fibrous connective tissue in assorted organs or tissues of the body. Drugs used in the treatment of idiopathic pulmonary fibrosis function to lessen lung fibrosis and inflammation by focusing on various signaling routes implicated in fibrosis. For instance, in December 2022, the American Lung Association, a lung-related organization based in the US, reported that approximately 207,000 people in the US were afflicted, with nearly 58,000 new instances of idiopathic pulmonary fibrosis identified annually. This disease is found to be more prevalent among males than females and primarily impacts individuals aged 50 and above. Hence, the escalating prevalence of fibrotic disease impels the growth of the idiopathic pulmonary fibrosis market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp
#How Does the ProjectedIdiopathic Pulmonary Fibrosis Market Growth Compare Over the Forecast Period?
The market for idiopathic pulmonary fibrosis has seen robust expansion in the recent past. The forecasted growth is from $4.15 billion in 2024 to $4.39 billion in 2025, representing a compound annual growth rate (CAGR) of 5.6%. This impressive historic growth is credited to factors such as a growing aged population, limited possibilities for treatment, increased awareness of the disease, and advancements in healthcare infrastructure.
Anticipated robust expansion is expected in the idiopathic pulmonary fibrosis market in the coming years. The market is predicted to reach $5.74 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.0%. This expected increase during the forecast period can be credited to extensive research and development efforts, the employment of precision medicine, a rise in disease incidence, advances in biomarker creation, and government support and funding. Future trends during the forecast period are set to include enhancements in diagnostic methods, the appearance of targeted treatments, the introduction of telemedicine and remote monitoring, combination therapies, and innovation in lung transplants.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12579
What Are the Most Significant Market Trends Transforming theIdiopathic Pulmonary Fibrosis Market?
The trend of product innovation is emerging strongly in the idiopathic pulmonary fibrosis market. Major players in this market are concentrating on the development of novel products to consolidate their standing and achieve a competitive edge. For example, Sandoz, a generics and biosimilars manufacturing firm based in Switzerland, introduced in May 2022 a generic pirfenidone, which is the first AB-rated equivalent to Genentech’s Esbriet, specifically designed for the treatment of those affected by idiopathic pulmonary fibrosis (IPF). Now, this prescribed oral medication is available to patients through specialty pharmacies, with eligible patients having the advantage of a USD 0 co-pay program.
What Are the Top Market Players Propelling the Growth of theIdiopathic Pulmonary Fibrosis Industry?
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Which Primary Segments of the Idiopathic Pulmonary Fibrosis Market Are Driving Growth and Industry Transformations?
The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Idiopathic Pulmonary Fibrosis Market?# Market?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Idiopathic Pulmonary Fibrosis Maret 2025, By The Business Research Company:
Overactive Bladder Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report
Pulmonary Arterial Hypertension Global Market Report 2024
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
